Our current finding showed that HELQ and XAB2 expressions in the ascites tumor cells correlated with HGSC patient's response to platinum-based chemotherapy and clinical outcomes indicate the potentiality of HELQ and XAB2 as independent biomarkers to predict HGSC patients' response to platinum drugs. Here, XAB2 is linked to neoplasm.